Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4277 - Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells

Date

11 Sep 2017

Session

Poster display session

Topics

Cancer Biology;  Hepatobiliary Cancers

Presenters

Xiaojin Li

Citation

Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361

Authors

X. Li1, A. Xu1, H. Li2, B. Zhang1, B. Cao2, J. Huang1

Author affiliations

  • 1 Experimental Center;national Clinical Research Center For Digestive Disease, Beijing Friendship Hospital, Capital Medical University, 100050 - Beijing/CN
  • 2 Department Of Oncology, Beijing Friendship Hospital, Capital Medical University, 100050 - Beijing/CN
More

Resources

Abstract 4277

Background

Although apatinib has been demonstrated with potential antitumor activity to multiple solid tumors, the underlying mechanism of apatinib for the treatment of hepatocellular carcinoma (HCC) remains unclear. In the present study, we explore if there is any direct suppression effect of apatinib on HCC cells and its relevant targets.

Methods

To determine the role of apatinib, we investigated its effect on viability, colony formation, apoptosis, migration of 6 HCC cell lines in vitro, and HCC progression in mice model. Using a phospho-receptor tyrosine kinase pathway array with 49 different tyrosine kinases, we screened and verified the tyrosine kinase targets involved in apatinib therapy.

Results

Apatinib treatment significantly inhibited HCC cell viability, proliferation, colony formation, migration, and enhanced cell apoptosis in a concentration-dependent manner (p

Conclusions

These novel data suggested that the apatinib may have a direct anti-HCC effects as a direct multi-target RTK inhibitor of HCC cells and a promising potentiality in HCC clinical therapies.

Clinical trial identification

Legal entity responsible for the study

Xiaojin Li

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.